LEO Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases
- LEO Pharma A/S acquires minority stake in PellePharm and provides additional non-dilutive capital to fund PellePharm development programs; obtains option to acquire all shares in PellePharm
- PellePharm and stockholders eligible to receive up to an aggregate of US$760 million including equity investment; development and commercialization support; merger consideration; and development, regulatory and commercial milestone payments
- PellePharm on track to commence pivotal Phase 3 trial for Gorlin Syndrome in 1Q2019